Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Pension Schemes Bill a framework for the future of the LGPS
The Pension Schemes Bill is a significant piece of legislation which will make wholesale structural changes across the pensions landscape. In this art
Will the Pensions Commission fix pension under saving
On 21 July 2025, the UK Government revived the Pensions Commission to tackle systemic pension under-saving and pension adequacy issues. The revived co
Climate and geopolitical shocks managing hyper volatility
Climate change intensifies geopolitical risk, creating hyper-volatility. How can organisations protect themselves against the resulting extreme, rapid

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.